RxDoctor Payments DataLook up a doctor →

Abdallah Altarshan, MD

Endocrinology, Diabetes & Metabolism · Evergreen Park, ILNPI 1174582811

Payments from drug & device makers

$131,795in general payments, 2019–2025

Across 845 payments — averaging $155.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$83K
  • Johnson & Johnson$30K
  • Sanofi-aventis U.S. LLC$4K
  • Insulet Corporation$1K
  • Mannkind Corporation$1K
  • Abbott$1K
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk193$83,247
Johnson & Johnson60$30,406
Sanofi-aventis U.S. LLC52$3,535
Insulet Corporation36$1,369
Mannkind Corporation50$1,136
Abbott20$1,046
Lilly USA, LLC48$1,030
Boehringer Ingelheim36$904
Corcept Therapeutics38$881
AstraZeneca42$877
Dexcom, Inc.14$830
Amgen(2 entities)27$686
Xeris Pharmaceuticals, Inc.26$636
Preventric Diagnostics, Inc.1$395
Bayer15$358
AbbVie(2 entities)17$339
Amarin Pharma, Inc.12$297
Recordati_rare_diseases_inc.8$242
Intuity Medical Inc6$236
Shire North American Group Inc7$209
Ultragenyx Pharmaceutical Inc.10$198
Ascensia Diabetes Care US Inc.6$196
Radius Health, Inc.8$181
Tandem Diabetes Care, Inc.4$175
Ascendis Pharma Endocrinology Inc4$174
BD2$168
Cequr Corporation2$166
Novartis6$111
IBSA Pharma Inc.7$111
Nestle Healthcare Nutrition Inc.7$106
Antares Pharma, Inc.7$99
Neurocrine Biosciences, Inc.3$91
BETA Bionics, Inc.5$82
Sequel Med Tech, LLC3$82
Astellas Pharma US Inc4$81
Lundbeck LLC3$65
Pfizer2$59
Madrigal Pharmaceuticals2$59
Echosens North America, Inc.3$56
Halozyme Inc3$55
Arbor Pharmaceuticals, Inc.3$52
Biohaven Pharmaceutical Holding Company Ltd.2$47
Kyowa Kirin, Inc.2$45
Clarus Therapeutics Inc.3$43
Exact Sciences2$42
Biohaven Pharmaceuticals, Inc.2$39
Roche Diabetes Care, Inc.2$33
Amneal Pharmaceuticals LLC2$30
Boston Scientific1$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$27
Sumitomo Pharma America, Inc.1$27
Otsuka America Pharmaceutical, Inc.1$26
Tactile Systems Technology Inc1$26
Merck2$24
Genentech USA, Inc.1$23
Amryt Pharma Holdings Ltd1$22
Sunovion Pharmaceuticals Inc.1$21
Melinta Therapeutics, LLC1$20
Hologic Sales And Service, LLC1$20
Inspire Medical Systems, Inc.1$20

How this compares

$131,795 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024
$279,609
Medicare patients
804
Services billed
4,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Evergreen Park

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →